Pfizer is enrolling healthy adults to test a reformulated COVID-19 vaccine that matches the hugely contagious omicron variant, to see how it compares with the original shots.
- Pfizer is enrolling healthy adults to test a reformulated COVID-19 vaccine that matches the hugely contagiousPfizer and its partner BioNTech announced the study on Tuesday.
The original vaccines still offer good protection against severe illness and death. Studies in the U.S. and elsewhere have made clear that adding a booster dose strengthens that protection and improves the chances of avoiding even a milder infection.Tuesday echoes data from Britain and South Africa that omicron infections cause less severe illness — at least in part because so many people have some protection from vaccination or prior infection.
Full study results will take many months as volunteers receive multiple vaccine doses — and as researchers measure how long virus-fighting antibodies remain at high levels after an omicron-adapted dose versus the regular booster.
Argentina Últimas Noticias, Argentina Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Covid-19 news: Strain on health services led to extra non-covid deathsToday’s covid-19 news: · 4000 excess non-covid 19 deaths occurred in England during first year of pandemic · Acute phase of pandemic could end in 2022 with improved vaccination rates, says WHO · Israel recommends fourth vaccine dose for all adults
Leer más »
Pfizer, BioNTech begin omicron-specific COVID-19 vaccine studyCOVID-19 vaccine-makers Pfizer and BioNTech announced Tuesday that the companies would test an omicron-specific vaccine candidate in healthy adults ages 18 to 55.
Leer más »
Pfizer says it's starting clinical studies of an omicron-based COVID-19 vaccinePfizer and BioNTech said Tuesday they've stated clinical trials for an omicron-based COVID-19 vaccine.
Leer más »
Pfizer launches study of omicron-specific COVID-19 vaccineBoosters still protect against severe disease.
Leer más »